Plasma nitric oxide in dogs with pulmonary hypertension secondary or not to left-sided heart disease

被引:1
作者
Braz, J. B. [1 ]
Beluque, T. [1 ]
Ampuero, R. A. N. [1 ]
Canola, R. A. M. [1 ]
Batalhao, M. . E. [2 ]
Carnio, E. C. [2 ]
Camacho, A. A. [1 ]
机构
[1] UNESP, Univ Estadual Paulista Julio Mesquita Filho, Jaboticabal, SP, Brazil
[2] Univ Sao Paulo, Univ Estado Sao Paulo, Ribeirao Preto, SP, Brazil
关键词
hypoxia; nitrate; nitrite; pulmonary arterial pressure; pulmonary vasculature; CLINICAL-EFFICACY; SYNTHASE; SILDENAFIL; MECHANISMS; TADALAFIL; FAILURE; NITRATE; LUNGS;
D O I
10.1590/1678-4162-12528
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Nitric oxide (NO) is an important mediator responsible for vasodilation in pulmonary hypertension (PH) in humans. Based on human literature, it is suggested that in dogs there is also NO production decrease in lung tissue in the presence of PH with hypoxia. Therefore, the aim of this research was to determine the indirect plasmatic NO concentration in dogs with PH secondary or not to the left-side heart disease (LHD) and also with low, intermediate and high probability of PH to characterize the NO involvement on PH in dogs. Blood samples were collected from 35 dogs with probability of PH to NO measurement. NO concentration was estimated by the nitrite/nitrate concentration, and it was significantly different (p=0.002) in dogs with PH secondary to LHD (median=14 mu M, range 11.19-16.59) and not secondary to LHD (median=25.88 mu M, range 15.08-36.71). However, this was not significant for the probability of low, intermediate, and high PH, although there was a tendency for NO concentration to be higher in dogs with high PH. The results of this study demonstrate that there is release of NO in dogs with PH, as well as that its dosage could differentiate dogs with PH secondary to LHD from dogs with non-secondary PH.
引用
收藏
页码:161 / 173
页数:13
相关论文
共 37 条
  • [1] The effect of sildenafil on pulmonary haemodynamics in a canine model of chronic embolic pulmonary hypertension
    Akabane, Ryota
    Sakatani, Atsushi
    Ogawa, Mizuki
    Nagakawa, Masayoshi
    Miyakawa, Hirosumi
    Miyagawa, Yuichi
    Takemura, Naoyuki
    [J]. RESEARCH IN VETERINARY SCIENCE, 2020, 133 : 106 - 110
  • [2] Clinical Efficacy of Sildenafil in Treatment of Pulmonary Arterial Hypertension in Dogs
    Brown, A. J.
    Davison, E.
    Sleeper, M. M.
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2010, 24 (04) : 850 - 854
  • [3] Nitrite Signaling in Pulmonary Hypertension: Mechanisms of Bioactivation, Signaling, and Therapeutics
    Bueno, Marta
    Wang, Jun
    Mora, Ana L.
    Gladwin, Mark T.
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2013, 18 (14) : 1797 - 1809
  • [4] Cerqueira Nereide Freire, 2002, Acta Cir. Bras., V17, P417
  • [5] Chester Adrian H, 2017, Glob Cardiol Sci Pract, V2017, P14, DOI 10.21542/gcsp.2017.14
  • [6] The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction
    Chirinos J.A.
    Zamani P.
    [J]. Current Heart Failure Reports, 2016, 13 (1) : 47 - 59
  • [7] Inhaled nebulized nitrite and nitrate therapy in a canine model of hypoxia-induced pulmonary hypertension
    Cortes-Puch, Irene
    Sun, Junfeng
    Schechter, Alan N.
    Solomon, Steven B.
    Park, Ji Won
    Feng, Jing
    GilHard, Cameron
    Natanson, Charles
    Piknova, Barbora
    [J]. NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2019, 91 : 1 - 14
  • [8] Nitric oxide and myocardial function in heart failure: friend or foe?
    Cotton, JM
    Kearney, MT
    Shah, AM
    [J]. HEART, 2002, 88 (06) : 564 - 566
  • [9] de Laforcade AM, 2003, J VET INTERN MED, V17, P315, DOI 10.1892/0891-6640(2003)017<0315:SNANID>2.3.CO
  • [10] 2